Lineage Cell Therapeutics, Inc. (LCTX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
LCTX Insider Trading Activity
LCTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $6,084,335 | 7 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| BROADWOOD PARTNERS, L.P. | 1 | $6M | 0 | $0 | $6M | |
| Culley Brian M | President and CEO | 2 | $34,500 | 0 | $0 | $34,500 |
| Mulroy Michael H. | director | 1 | $22,640 | 0 | $0 | $22,640 |
| Howe Jill Ann | Chief Financial Officer | 2 | $18,195 | 0 | $0 | $18,195 |
| Samuel George A. III | General Counsel | 1 | $9,000 | 0 | $0 | $9,000 |
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Insider Activity of Lineage Cell Therapeutics, Inc.
Over the last 12 months, insiders at Lineage Cell Therapeutics, Inc. have bought $6.08M and sold $0 worth of Lineage Cell Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lineage Cell Therapeutics, Inc. have bought $4.43M and sold $1.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. () — $6M. Culley Brian M (President and CEO) — $34,500. Mulroy Michael H. (director) — $22,640.
The last purchase of 7,894,737 shares for transaction amount of $6M was made by BROADWOOD PARTNERS, L.P. () on 2025‑01‑27.
List of Insider Buy and Sell Transactions, Lineage Cell Therapeutics, Inc.
| 2025-01-27 | BROADWOOD PARTNERS, L.P. | 7.89M 4.4378% | $0.76 | $6M | -18.37% | |||
| 2024-11-26 | Howe Jill Ann | Chief Financial Officer | 15,000 0.0082% | $0.59 | $8,850 | -13.70% | ||
| 2024-11-26 | Samuel George A. III | General Counsel | 15,000 0.0083% | $0.60 | $9,000 | -13.70% | ||
| 2024-11-22 | Mulroy Michael H. | director | 40,000 0.0237% | $0.57 | $22,640 | +4.25% | ||
| 2024-11-21 | Culley Brian M | President and CEO | 40,000 0.0213% | $0.60 | $24,000 | -12.72% | ||
| 2024-08-16 | Howe Jill Ann | Chief Financial Officer | 10,500 0.0059% | $0.89 | $9,345 | -29.54% | ||
| 2024-05-24 | Culley Brian M | President and CEO | 10,000 0.0054% | $1.05 | $10,500 | -21.01% | ||
| 2024-02-08 | BAILEY DON M | director | 96,155 0.0563% | $1.04 | $100,001 | -15.51% | ||
| 2024-02-06 | BROADWOOD PARTNERS, L.P. | 6.73M 3.9412% | $1.04 | $7M | -17.65% | |||
| 2023-12-29 | Jayasuriya Anula | director | 10,000 0.0057% | $1.09 | $10,900 | -11.37% | ||
| 2022-03-31 | Culley Brian M | President and CEO | 6,400 0.0037% | $1.53 | $9,792 | -11.04% | ||
| 2022-03-28 | Amin Dipti | 35,000 0.0227% | $1.63 | $57,050 | -7.43% | |||
| 2022-03-25 | Culley Brian M | President and CEO | 5,250 0.0029% | $1.38 | $7,245 | -7.43% | ||
| 2022-03-24 | Mulroy Michael H. | 7,000 0.004% | $1.40 | $9,800 | -4.86% | |||
| 2022-03-23 | BRADSHER NEAL C | 0 – | $0 | $0 | -0.72% | |||
| 2021-12-29 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 37,695 0.0227% | $2.45 | $92,438 | -43.21% | |
| 2021-12-28 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 501,588 0.298% | $2.45 | $1.23M | -43.70% | |
| 2021-06-29 | Sale | Russell Angus C. | director | 4,720 0.0029% | $2.97 | $14,018 | -29.69% | |
| 2021-06-29 | Sale | ANDREWS DEBORAH J | director | 19,142 0.0117% | $2.93 | $56,086 | -29.69% | |
| 2021-06-28 | Sale | Culley Brian M | President and CEO | 450,000 0.2743% | $2.87 | $1.29M | -28.72% |
Insider Historical Profitability
| BROADWOOD PARTNERS, L.P. | 49560992 21.7034% | $23.29M | 20 | 1 | +9.11% | |
| Mulroy Michael H. | director | 298555 0.1307% | $140,320.85 | 2 | 0 | <0.0001% |
| Culley Brian M | President and CEO | 194842 0.0853% | $91,575.74 | 5 | 1 | <0.0001% |
| Howe Jill Ann | Chief Financial Officer | 25500 0.0112% | $11,985.00 | 2 | 0 | |
| Samuel George A. III | General Counsel | 22184 0.0097% | $10,426.48 | 1 | 0 | |
| BRADSHER NEAL C | 34265485 15.0053% | $16.1M | 4 | 0 | <0.0001% | |
| KINGSLEY ALFRED D | See Remarks | 5781555 2.5318% | $2.72M | 13 | 8 | |
| WEST MICHAEL D | Co-Chief Executive Officer | 882864 0.3866% | $414,946.08 | 3 | 1 | +1.12% |
| SEGALL JUDITH | Vice President & Secretary | 520415 0.2279% | $244,595.05 | 0 | 4 | |
| Peabody Robert | Sr. VP, COO, and CFO | 315777 0.1383% | $148,415.19 | 1 | 1 | +6.44% |
| STERNBERG HAL | Vice President | 254270 0.1113% | $119,506.90 | 0 | 1 | |
| WAITZ HAROLD D | Vice President | 184246 0.0807% | $86,595.62 | 0 | 2 | |
| BAILEY DON M | director | 158801 0.0695% | $74,636.47 | 1 | 0 | <0.0001% |
| Cartt Stephen LaHue | director | 155125 0.0679% | $72,908.75 | 3 | 0 | +6.94% |
| LICHTINGER PEDRO | director | 126250 0.0553% | $59,337.50 | 2 | 0 | <0.0001% |
| FARRELL STEPHEN C | director | 97450 0.0427% | $45,801.50 | 6 | 0 | <0.0001% |
| MOHANTY ADITYA P. | Co-Chief Executive Officer | 89696 0.0393% | $42,157.12 | 1 | 0 | <0.0001% |
| Russell Angus C. | director | 87500 0.0383% | $41,125.00 | 1 | 1 | <0.0001% |
| Amin Dipti | 35000 0.0153% | $16,450.00 | 1 | 0 | <0.0001% | |
| SCHLACHET DAVID | director | 32050 0.014% | $15,063.50 | 1 | 0 | +11.75% |
| SEINBERG STEVEN A | Chief Financial Officer | 22500 0.0099% | $10,575.00 | 0 | 4 | |
| ANDREWS DEBORAH J | director | 15578 0.0068% | $7,321.66 | 5 | 1 | <0.0001% |
| BURNS ARNOLD I | director | 15000 0.0066% | $7,050.00 | 1 | 0 | <0.0001% |
| COHEN ABRAHAM E | director | 10000 0.0044% | $4,700.00 | 1 | 0 | <0.0001% |
| Jayasuriya Anula | director | 10000 0.0044% | $4,700.00 | 1 | 0 | <0.0001% |
| Patton Stephana Eilene | General Counsel | 7500 0.0033% | $3,525.00 | 1 | 0 | <0.0001% |
| GARCIA PETER S | Chief Financial Officer | 7000 0.0031% | $3,290.00 | 2 | 0 | <0.0001% |
| Roberts Brandi | CFO & SVP, Finance | 5000 0.0022% | $2,350.00 | 1 | 0 | <0.0001% |
| Leavitt Chase C. | General Counsel/Secretary | 5000 0.0022% | $2,350.00 | 1 | 0 | <0.0001% |
| TEW WILLIAM P PHD | Chief Commercial Officer | 3265 0.0014% | $1,534.55 | 0 | 5 | |
| VON ESCHENBACH ANDREW C. | director | 3000 0.0013% | $1,410.00 | 1 | 0 | <0.0001% |
| SKIBSTED RUSSELL | Chief Financial Officer | 2000 0.0009% | $940.00 | 1 | 0 | <0.0001% |
| BERGER FRANKLIN M | director | 500 0.0002% | $235.00 | 1 | 0 | <0.0001% |
| GREGG VALETA A | director | 0 0% | $0 | 0 | 8 | |
| Hogge Gary S. | SVP,Clinical & Medical Affairs | 0 0% | $0 | 0 | 2 | |
| Hernandez Alexandra | Sr Director Finance/Controller | 0 0% | $0 | 0 | 1 |
Historical Insider Profitability vs. Competitors
Lineage Cell Therapeutics, Inc. (LCTX) | $54,751,750 | 62 | -1.03% | $107.33M |
$48,218,096 | 42 | 0.89% | $105.43M | |
$64,487,106 | 32 | -22.92% | $116.94M | |
$35,092,436 | 31 | 38.62% | $98.94M | |
$63,049,419 | 31 | 2.87% | $109.89M | |
$40,617,659 | 23 | 2.15% | $97.16M | |
$294,424,120 | 20 | 1.33% | $114.6M | |
$178,593,887 | 15 | -14.86% | $109.39M | |
$91,870,774 | 13 | 3.64% | $116.66M | |
$10,143,329 | 12 | 11.84% | $111.57M | |
$145,194 | 11 | -27.37% | $114.96M | |
$68,692,148 | 6 | -39.10% | $114.78M | |
$556,839 | 5 | 13.42% | $106.51M | |
$30,149,552 | 3 | -66.74% | $96.27M | |
$16,003,671 | 3 | 55.38% | $95.63M | |
$32,289,200 | 3 | -5.46% | $110.99M | |
$20,020,000 | 1 | -75.24% | $100.27M | |
$63,731 | 1 | -19.50% | $97.55M | |
$3,620 | 1 | 94.16% | $96.34M |
LCTX Institutional Investors: Active Positions
| Increased Positions | 61 | +50.41% | 22M | +22.61% |
| Decreased Positions | 35 | -28.93% | 9M | -8.88% |
| New Positions | 26 | New | 13M | New |
| Sold Out Positions | 16 | Sold Out | 6M | Sold Out |
| Total Postitions | 147 | +21.49% | 110M | +13.73% |
LCTX Ownership Change vs Market
Institutional Investor Ownership
| Broadwood Capital Inc | $20,458.00 | 18.27% | 41.67M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $5,624.00 | 5.02% | 11.45M | +1M | +13.46% | 2025-03-31 |
| Vanguard Group Inc | $4,239.00 | 3.79% | 8.63M | +31,933 | +0.37% | 2024-12-31 |
| Perceptive Advisors Llc | $3,553.00 | 3.17% | 7.24M | +7M | New | 2024-12-31 |
| Defender Capital, Llc. | $3,099.00 | 2.77% | 6.31M | +347,525 | +5.83% | 2025-03-31 |
| Raffles Associates Lp | $2,697.00 | 2.41% | 5.49M | +984,307 | +21.84% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $1,938.00 | 1.73% | 3.95M | +4M | New | 2024-12-31 |
| Geode Capital Management, Llc | $1,812.00 | 1.62% | 3.69M | +11,206 | +0.3% | 2024-12-31 |
| State Street Corp | $1,313.00 | 1.17% | 2.67M | +66,160 | +2.54% | 2024-12-31 |
| Dafna Capital Management Llc | $1,233.00 | 1.1% | 2.51M | +1M | +85.93% | 2024-12-31 |